NIS Considerations - Taiwan An overview of the considerations when conducting Non-interventional Studies in Taiwan
|
|
- Emmeline Tyler
- 6 years ago
- Views:
Transcription
1 NIS Considerations - Taiwan An overview of the considerations when conducting Non-interventional Studies in Taiwan Stuart McCully Compliance Healthcheck Consulting UK Ltd NIS-C-TW
2 Table of Contents Disclaimer! 8 Regulatory Requirements! 9 COUNTRY-SPECIFIC REGULATORY REQUIREMENTS 9 REGULATORY BODIES 9 DEFINITIONS 10 Human Trial Research 10 Human Research 10 Human Specimens 10 Delinking 10 REGULATORY FRAMEWORK 11 Applicable Legislation & Guidance 11 SUMMARY OF THE NIS REQUIREMENTS IN TAIWAN 13 APPROVAL & NOTIFICATION REQUIREMENTS 14 WHO IS RESPONSIBLE FOR WHAT? 15 REGULATORY SUBMISSIONS ROADMAP 16 REGULATORY SUBMISSIONS DOCUMENTS 17 REGULATORY REQUIREMENTS - USEFUL LINKS 18 Study Conduct Considerations! 21 RESEARCH USING HUMAN SUBJECTS 21 POST-MARKETING SURVEILLANCE STUDIES (PMS) 21 ETHICAL REVIEW 22 1
3 IRB Review 22 List of Taiwan IRBs 22 IRB Penalties 24 IRB Review Challenges 25 Expedited IRB Review 25 IRB Conflicts of Interest 25 The Joint Institutional Review Board (JIRB) 26 JIRB Application Process for Post-Marketing Surveillance Studies (PMS) 27 JIRB Application Form 29 CONTRACTS 34 CONSENT 35 Consent Requirements 35 Informed Consent for Post-Marketing Surveillance Studies 35 Consent Process 36 Adults 37 Minors 37 Penalties for Non-Compliance 37 ABORIGINES 37 STUDY SITES 38 Site Authorisation 38 Investigator Training Requirements 38 LOCAL REPRESENTATION 38 Special Requirements for CROs 39 MATERIAL ACQUIRED DURING RESEARCH 39 ANNUAL REPORTS 40 JIRB Annual Report Submission Process 40 JIRB Annual Report Form 41 SAFETY REPORTING 45 2
4 Post-Marketing Surveillance 45 Marketed Medicinal Products 45 Definition - Serious Adverse Drug Reaction 45 Management of Reporting 46 For Fatal or Life-threatening Serious Adverse Reactions 46 For All Other Serious Adverse Reactions 47 For Non-Serious Adverse Reactions 47 How to Report 47 Newly Marketed Medical Products 47 Definition - New Drug 48 Schedule of Reporting PSUR 48 Content in the Periodic Safety Update Report (PSUR) 48 Final Summary Bridging Report 49 How to Report 49 PROTOCOL AMENDMENTS 51 JIRB Protocol Amendment Form A - Signed by Each PI 52 JIRB Protocol Amendment Form B - Signed by the Chief Investigator on Behalf of the PIs 55 END OF STUDY NOTIFICATION 59 IRB Closure Report 59 STUDY CONDUCT CONSIDERATIONS - USEFUL LINKS 63 Data Privacy Considerations! 65 DEFINITIONS 65 Personal Information 65 Personal Information File 65 Collection 65 Processing 66 Use 66 3
5 International Transmission 66 Government Agency 66 Non-Government Agency 66 The Party 66 COLLECTION OF PERSONAL INFORMATION 67 CONSENT 67 Consent Obligations 67 Content of Consent 67 RIGHTS OF THE INFORMATION DONOR 68 SECURITY OF PERSONAL INFORMATION FILES 68 DAMAGES AND CLASS LITIGATION 69 Liability for Illegal Collection, processing and Use of Personal Information 69 The Right to Claim for Damage Compensation 69 DATA PRIVACY CONSIDERATIONS - USEFUL LINKS 70 Human Tissue Research! 71 DEFINITIONS 71 Specimen(s) 71 Specimen Donor 71 Specimen User 71 Specimen Custodian 72 ID Encoding 72 De-linking 72 Remnant Specimen(s) 72 COLLECTION AND USE OF HUMAN SPECIMENS FOR RESEARCH 72 Ethics Approval 73 Informed Consent Requirements 73 Collection of Specimens from an Embryo or Fetus 74 4
6 Notification of Commercial Interests 75 Notification of Results that have a Significant Impact on the Personal Health of a Donor 76 Specimen to be Used within the Constraints of the Donor Consent 76 Refusal or Withdrawal of Consent 76 Management of Specimens 77 Storage and/or Destruction of Specimens on Completion of Studies 77 Data Privacy 77 Transfer of Specimens to Foreign Countries 78 Consent Waiver 78 RE-USE OF MATERIAL ACQUIRED DURING RESEARCH 78 JIRB APPLICATION PROCESS FOR GENETIC RESEARCH STUDIES 80 HUMAN TISSUE RESEARCH CONSIDERATIONS - USEFUL LINKS 82 Best Practice Considerations! 83 CLINICAL RESEARCH 83 Transparency 83 Distinct from Promotion 83 Post-Marketing Surveillance Studies (PMS) 84 Mandatory Medical Components for Post-Marketing Studies 84 Essential Components for Post-Marketing Studies 85 Format for PMS Registry System 86 Further PMS Considerations 86 What is the definition of a PMS? 86 What are the scopes of the post marketing studies that should be posted on IRPMA the website? 87 Following the approval by the IRB, JIRB, when should the PMS be posted on IRPMA website? 87 Are all items in the template for PMS registry system necessary? (The Objective, No. of Sites, No. of Patients) 87 5
7 ENGAGING HEALTHCARE PROFESSIONALS AS CONSULTANTS 88 GIFTS 88 Prohibition of Cash & Personal Gifts 88 Promotional Aids 89 What can be given as a promotional aid? 89 How to justify the promotional aids in Article 7.5.2? Are electronic goods (such as a USB flash disk) included in the scope of personal gifts as stated in Article 7.5.1? 89 Items of Medical Utility 90 What kinds of items are envisaged as being items of medical utility? 90 Are lucky draws allowed? 90 Cultural Courtesy Gifts 90 EVENTS 91 Scientific and Educational Objectives 91 Is there any restriction for accommodation, number of participants, or ceiling when sponsor a symposium, congress or other medical health care or educational program? 91 Events Involving Foreign Travel 91 When is it appropriate and justified for a company to organize or sponsor an event for healthcare professionals outside of their home country? 91 Promotional Information at Events 92 Appropriate Venue 93 In case of one-day program, if participants who have difficulties to return to their home town on that day due to traffic problem, what shall we do? 93 Limits of Hospitality 94 Hospitality should be limited to refreshments and/or meals incidental to the main purpose of the Event. What is the definition of the Event? 94 Sponsorship 94 Is there any consideration for sponsoring HCPs attending overseas event? 95 In regard to flight tickets under sponsorship, in case that there is no business class but only economy and first class available, what shall the company do? 95 Guests 96 6
8 While attending an event, are the invitees allowed to bring guests? 96 Events - Further Considerations 96 HCP Payment for Service 96 Is it necessary to have a contract with the invited healthcare professional as speakers or presenters for the payment of honorarium and related travelling and boarding expenses? 97 For the honorarium for local speaker to lecture overseas or to lecture in international symposia in Taiwan, should the international norms or a limit of up to NT$5,000/hr be applied? 97 How to calculate additional payment? 97 ENTERTAINMENT 98 The IRPMA Code prohibits companies from providing entertainment, leisure and social activities to healthcare professionals and other stakeholders. Are there exceptions to this rule? 98 Are individual social activities with healthcare professionals such as golf, music concert, etc. allowed? 98 BEST PRACTICE CONSIDERATIONS - USEFUL LINKS 100 NIS Definitions! 101 EUROPEAN NIS DEFINITIONS 101 NIS DEFINITIONS 101 Non-interventional Study (NIS) 101 Post-authorisation Safety Study (PASS) 102 Post-authorisation Efficacy Studies (PAES) 102 Common NIS Terminology! 103 COMMONLY USED NIS TERMS 103 COMMON NIS TERMINOLOGY 103 7
9 Disclaimer Although this Compilation contains information of a legal nature, it has been developed for informational purposes only and does not constitute legal advice or opinions as to the current operative laws, regulations, or guidelines of any jurisdiction. In addition, because new standards are issued on a continuing basis, this Compilation is not an exhaustive source of all current applicable laws, regulations, and guidelines relating to non-interventional studies. While reasonable efforts have been made to assure the accuracy and completeness of the information provided, researchers and other individuals should check with local authorities and/or research ethics committees before starting research activities. 8
10 Regulatory Requirements COUNTRY-SPECIFIC REGULATORY REQUIREMENTS REGULATORY BODIES Competent Authority Research Ethics Committees Data Protection Agency Pharmaceutical Self-Regulation Body Pharmaceutical Code of Practice Taiwan Food and Drug Administration (TFDA)* Joint Institution Review Board (JIRB) Not Applicable** International Research-Based Pharmaceutical Manufacturers Association (IRPMA) IRPMA Code of Practice 2012^ * The regulatory system for the safety and quality of food, drug, medical device, and cosmetics is critical to the public health. As these products are intimately involved in people s daily life and health as well as medical welfare, the Department of Health had been striving to facilitate organizational reform by focusing on consumer health in terms of food and drug safety. Consolidation of the Bureau of Food Safety, the Bureau of Pharmaceutical Affairs, the Bureau of Food and Drug Analysis and the Bureau of Controlled Drugs into the Taiwan Food and Drug Administration (TFDA) was completed on January 1st, 2010, following the promulgation of the TFDA Organization Act on June 3rd, 2009 (Source - about the FDA). ** The Personal Information Protection Act (PIPA) does not provide for a single oversight body and does not create a data protection agency. Enforcement is left to the Ministries responsible for each industry sector. ^ Effective 1st September 2012, the IRPMA Code of Practice (Updated 2012) replaces the 2007 IRPMA Code of Marketing Practices. Member companies of IRPMA must incorporate this Code into existing internal codes no later than 1st September
11 DEFINITIONS Human Trial Research A human trial research (hereinafter Human Trial shall be conducted prior to the registration of a new drug or medical device or before a medical care institution lists a new medical technology as a regular medical disposition item (as per Article 2 of the Regulations on Human Trials ). Human Research Engaging in research on behavioral ecology, physiology, psychology, genetics, medicine, and the like by obtaining, investigating, analyzing, and applying data related to human specimens or individuals (as per General Provision 4 of the Human Research Act ). Human research shall include all processes seeking to acquire, analyze, and investigate human tissue or information concerning individual behavior, thinking, physiology, psychology, sociology, genetics, and medicine for the purpose of research (as per paragraph 2 of the DoH Human Research Ethics Policy Guidelines ). Human Specimens Human specimens" refers to human organs (including those from fetuses and corpses), tissue, cells, body fluids, or materials derived from test results (as per General Provision 4 of the Human Research Act ). Delinking Whereby once the research material or data has been coded or handled by other means, it will become impossible to link or compare it with any identifiable human research subjects (as per General Provision 4 of the Human Research Act ). 10
12 Study Conduct Considerations CONSIDERATIONS WHEN CONDUCTING NIS IN TAIWAN RESEARCH USING HUMAN SUBJECTS On December 9, 2011, Taiwan's legislature adopted a new law on the use of human subjects in research projects. Previously, research involving humans was governed by the non-binding Ethical Guidelines for Human Research, formulated by the Department of Health in (Taiwan Legislature Greenlights New Human Subject Research Law, TAIWAN TODAY (Dec. 12, 2011).) One key feature of the new law is that it makes informed consent by aborigines a precondition for any research involving them and for release of the research results. (Shih Hsiu-chuan, Legislature Passes Act on Using Human Subjects in Research, TAIPEI TIMES (Dec. 10, 2011).) The purpose of the Act on Human Research Subjects is to better protect the subjects' rights, because those rights "tend to be neglected and thus impinged upon, due to such factors as differential access to information and conflicts of interest between subjects and researchers." (Id.) The Act stipulates that research conducted on humans must respect the subjects' decision-making power, ensure a balance between risks and benefits, minimize infringements, and also attend to the fair assignment of the research burdens and the achievements alike, in order to safeguard the subjects' rights. (Jen-t'i yen-chiu fa [Act on Research Involving Human Subjects] (Dec. 9, 2011) arts. 1 & 2, Parliamentary Library Legislative Yuan website.) (Zeldin, 2011). POST-MARKETING SURVEILLANCE STUDIES (PMS) The objective of PMS study is to collect patient information and to explore the treatment experience in Taiwan. It involved the treatment of indication stated in the approved user guide of drugs. Basing on the Benchmarks of Marketing Practices announced by IRPMA, all the post- marketing drug trials must be approved by the Institutional Review Board, and PMS 21
13 study is no exception. As the drug is already in the market, the treatment is available for the patients. The emphasize of the Institutional Review Board is not to safeguard the safety of the patients going through the treatment, but to protect the privacy of the patients, and whether or not the patients agree to enable the drug manufacturer to access their medical records (as per Attachment 11 of the Human Subject Protection Handbook). ETHICAL REVIEW IRB Review To ensure the protection of human subjects in biomedical research studies, study protocols must be reviewed and approved by an IRB before patient recruitment (as per the JIRB Guidelines). The Human Research Act (2011) requires that a research plan must be approved by an ethics review committee before a research project that involves human subjects can proceed. The committee, to be set up by the research institute concerned, is to comprise a minimum of five disinterested persons of whom at least two-fifths are from outside the institution; neither gender, moreover, may exceed two-thirds of the membership. The Act requires that approved research projects undergo annual reviews. List of Taiwan IRBs The following list is by no means exhaustive and is only provided to aid the reader of this report in their initial IRB due diligence exercises. IRB Human Subject Research Ethics Committee Institutional Review Board, Taipei Veterans General Hospital Website goodexp/content.htm 22
14 PROTOCOL AMENDMENTS Protocol amendments must be approved by the applicable IRB before being implemented. The Joint Institutional Review Board (JIRB) has two amendment forms that are either signed by each individual instigator (Form A) or by the Chief Investigator (CI) on behalf of the Principal Investigators (Form B). Where, proposed protocol amendments are low risk they may be eligible for expedited IRB review. Expedited review requires only approval from the Chairman (or designee), rather than the full IRB committee. (Image Source: IRB of the Taichung Veterans General Hospital) 51
15 Data Privacy Considerations DATA PRIVACY AND DATA PROTECTION CONSIDERATIONS WHEN CONDUCTING NIS IN TAIWAN DEFINITIONS Personal Information The name, date of birth, I.D. Card number, passport number, characteristics, fingerprints, marital status, family, education, occupation, medical record, medical treatment, genetic information, sexual life, health examination, criminal record, contact information, financial conditions, social activities and other information which may be used to identify a natural person, both directly and indirectly (as per Article 2.1 of the Personal Information Protection Act). Personal Information File A collection of personal information built to allow information retrieval and management by automatic or non-automatic measures (as per Article 2.2 of the Personal Information Protection Act). Collection To collect personal information in any form and way (as per Article 2.3 of the Personal Information Protection Act). 65
16 Processing To record, input, store, compile, correct, duplicate, retrieve, delete, output, connect or internally transmit information for the purpose of establishing or using a personal information file (as per Article 2.4 of the Personal Information Protection Act). Use All methods of personal information use other than processing (as per Article 2.5 of the Personal Information Protection Act). International Transmission The cross-border processing or use of personal information (as per Article 2.6 of the Personal Information Protection Act). Government Agency Refers to a government agency or administrative juridical person at the central or local government level which is empowered to exercise sovereign power (as per Article 2.7 of the Personal Information Protection Act). Non-Government Agency Refers to the natural persons, juridical persons or groups other than those stated in the proceeding item (as per Article 2.8 of the Personal Information Protection Act). The Party Means an individual of whom the personal information has been collected, processed or used in accordance with this Law (as per Article 2.9 of the Personal Information Protection Act). 66
17 Human Tissue Research CONSIDERATIONS WHEN CONDUCTING STUDIES WITH HUMAN SAMPLES AND DATA IN TAIWAN DEFINITIONS Specimen(s) Cells, tissue, organs, body fluids or derivatives thereof (containing genetic material) taken from the human body, to include remnant specimens and specimens taken from an embryo, fetus or cadaver (as per Paragraph 2(1) of the DoH Guidelines for Collection and Use of Human Specimens for Research ). Specimen Donor A person from whom a specimen is collected (as per Paragraph 2(2) of the DoH Guidelines for Collection and Use of Human Specimens for Research ). Specimen User A person or institution who/that directly uses the specimen, directs another person to use the specimen or who/that may use the specimen in accordance with a specific relationship, such as a contract, with the specimen provider (as per Paragraph 2(3) of the DoH Guidelines for Collection and Use of Human Specimens for Research ). 71
18 Best Practice Considerations BEST PRACTICE CONSIDERATIONS WHEN CONDUCTING NIS IN TAIWAN CLINICAL RESEARCH Transparency Companies are committed to the transparency of clinical trials which they sponsor. It is recognized that there are important public health benefits associated with making clinical trial information more publicly available to healthcare practitioners, patients, and others. Such disclosure, however, must maintain protections for individual privacy, intellectual property and contract rights, as well as conform to legislation and current national practices in patent law (as per Section 9.1 of the IRPMA Code of Practice, 2012). Companies disclose clinical trial information as set out in the Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases (2009) and the Joint Position on the Publication of Clinical Trial Results in the Scientific Literature (2010) issued by the IFPMA, the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Japanese Pharmaceutical Manufacturers Association (JPMA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) (as per Section 9.1 of the IRPMA Code of Practice, 2012). Distinct from Promotion All human subject research must have a legitimate scientific purpose. Human subject research, including clinical trials and observational studies, must not be disguised promotion (as per Section 9.2 of the IRPMA Code of Practice, 2012). 83
19 POST-MARKETING SURVEILLANCE STUDIES (PMS) In accordance with Benchmark 9 of the IRPMA Code of Practice, 2012: All PMS shall go through JIRB, IRB or Ethics Committee All human studies including PMS must be approved and managed by Medical Director or equivalent CR Manager of member companies All PMS must be registered on the website of IRPMA PMS registry system IRB approval code or approval date should be shown on study-related documents Mandatory Medical Components for Post-Marketing Studies In accordance with Benchmark 9 of the IRPMA Code of Practice, 2012: Protocol to address scientific objectives To have specific scientific interest Pre-determined sample size justification based on study description Should be based on clinical & statistical significant meaning Patient consent obtained IRB approval secured Follow GCP Guideline Minimum to comply with TW DOH GCP Registry on IRPMA website Payment must be appropriate and according to study design. It must not be set to influence prescribing behavior Must reflect time & efforts from investigators 84
Establishment of Clinical Trial Infrastructure
Taiwan s Strategy in the Establishment of Clinical Trial Infrastructure Chei-Hsiang Chen, Ph. D. Director, Biotechnology and Pharmaceutical Industries Program Office, Ministry of Economic Affairs, Taiwan
More informationStanford University IRB Guidance On Data and Tissue Repositories
Stanford University IRB Guidance On Data and Tissue Repositories Databases, registries (data banks), and repositories (tissue banks) all involve the collection and storage of information and/or biological
More informationRules of Human Experimentation
Rules of Human Experimentation Elaine Larson CUMC IRB Chair Associate Dean for Research, School of Nursing Professor of Epidemiology, Mailman School of Public Health Oversight for Human Research Office
More informationHow did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949
ICH GCP Overview What is ICH? ICH is a joint initiative involving both the regulators and the industry as equal partners in the scientific and technical discussions of the testing procedures which are
More informationEIGHT BASIC ELEMENTS OF INFORMED CONSENT
1/6 This guidance addresses: o Eight Basic elements of informed consent o Additional elements of informed consent o Other information required by the IRB EIGHT BASIC ELEMENTS OF INFORMED CONSENT Required
More informationDATA SHARING AGREEMENT
DATA SHARING AGREEMENT Effective Date: This Data Sharing Agreement ( Agreement ) is effective as of the Effective Date between EMD Serono, One Technology Place, Rockland, MA 02370 and Name ( Institution
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria Question 1: What laws or regulations apply to an application for conducting a clinical
More informationHospital Authority (HA) Guide on Research Ethics (for Study Site & Research Ethics Committee)
Page 1 of 8 Hospital Authority (HA) Guide on Research Ethics (for Study Site & Version Effective Date 2 01/02/2015 Document Number HAHO-CE&TM-HA REC Author HA Head Office Steering Committee on Research
More informationA notice on the issuance of drug clinical trials, ethical review of the guiding principles
药物临床试验伦理审查工作指导原侧.doc 的翻译 A notice on the issuance of drug clinical trials, ethical review of the guiding principles State Food and Drug Administration Note [2010] No. 436 November 2, 2010 Release A notice
More information3. Human Biomedical Research. Defining Human Biomedical Research
PART B: SECTION III: HUMAN BIOMEDICAL RESEARCH HUMAN BIOMEDICAL RESEARCH 3. Human Biomedical Research Defining Human Biomedical Research 3.1. In this section, we consider what kinds of human biomedical
More informationGeneral Policies & Procedures. SV 5.0 Clean Harbors Vendor Code of Business Conduct and Ethics
1. Purpose This Code is intended to govern the conduct of Clean Harbors, Inc. and all of its subsidiaries Vendors when doing business with or on behalf of Clean Harbors, Inc. For the purpose of this Code,
More informationEFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY
EFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY PREAMBLE The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the
More informationEthics Committees/IRBs Today: Challenges for Efficiency and Quality
Marjorie A. Speers, Ph.D. President and CEO Ethics Committees/IRBs Today: Challenges for Efficiency and Quality Copyright 2013 AAHRPP All rights reserved Goal Clinical Research Globally Access to patients
More informationINSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience
INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience Umberto Filibeck Former Head of AIFA GCP Inspectorate and GCP Promotion Unit UNICRI Consultant for Projects on GCP of CTs in developing
More informationClinical Research: A Multifaceted Discipline
Clinical Research: A Multifaceted Discipline Anuradha Kulkarni a, Arun Bhatt b* a Senior Associate - Medical & Regulatory Affairs, Clininvent Research Pvt Ltd, A-302, Everest Chambers, Marol Naka, Andheri
More informationSupplier Code of Business Conduct and Ethics
Supplier Code of Business Conduct and Ethics Table of Contents 1. Definitions 2. Purpose 3. Policy Statement 4. Workplace Standards and Practices and Compliance with the Law 5. Health, Safety and Environmental
More informationGood Clinical Practice (GCP) & Clinical Trial Registries
Good Clinical Practice (GCP) & Clinical Trial Registries The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practice Forum November 14-17, 2004 Kate Maloney, RN, MS, CPHQ Manager,
More informationJPMA Code of Practice
JPMA Code of Practice (Established on January 16, 2013) (Enforced on April 1, 2013) (Revised on May 25, 2017) (Enforced on October 1, 2017) Japan Pharmaceutical Manufacturers Association (JPMA) [Preamble]
More informationHOSPITAL AUTHORITY (HA) GUIDE
Page 1 of 14 HOSPITAL AUTHORITY (HA) GUIDE ON RESEARCH ETHICS (for Study Site & Research Ethics Committee) Revision Number: 1 (The document supersedes HA RE001 Hospital Authority Guide for Cluster Research
More informationCell and Gene Therapy Medicinal Product Management Act (Draft) General Information
Cell and Gene Therapy Medicinal Product Management Act (Draft) General Information July 2017 At present there are still many diseases that cannot be cured by current medical technology and existing chemical
More informationThe Committee of Ministers, under the terms of Article 15.b of the Statute of the Council of Europe,
Recommendation CM/Rec(2015)5 of the Committee of Ministers to member States on the processing of personal data in the context of employment (Adopted by the Committee of Ministers on 1 April 2015, at the
More informationTrends in Oversight of Human Research Protections?
Trends in Oversight of Human Research Protections? Greg Koski, PhD, MD Associate Professor, Harvard Medical School Senior Scientist, James Mongan Institute for Health Policy Former Director, Office for
More informationOtsuka. Supporting. Supplier Code of Ethics and Professional Conduct
Supporting Otsuka Supplier Code of Ethics and Professional Conduct Otsuka America Pharmaceutical, Inc. (OAPI) Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) Otsuka Maryland Medicinal
More informationGCP Basics - refresher
p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History
More informationCODE OF CONDUCT Business ethics and compliance
CODE OF CONDUCT Business ethics and compliance BUSINESS PARTNERS Index FRESENIUS KABI BUSINESS PARTNER CODE OF CONDUCT 3 ABOUT US 4 FRESENIUS KABI S BUSINESS: CARING FOR LIFE FRESENIUS KABI S CORE VALUES
More informationto The Uganda Gazette No. 25, Volume CX, dated 5th May, 2017 Printed by UPPC, Entebbe, by Order of the Government No. 22.
STATUTORY INSTRUMENTS SUPPLEMENT No. 13 5th May, 2017 STATUTORY INSTRUMENTS SUPPLEMENT to The Uganda Gazette No. 25, Volume CX, dated 5th May, 2017 Printed by UPPC, Entebbe, by Order of the Government.
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
SOP #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional responsibilities
More informationMaintaining your Investigational Device Exemption (IDE) with the FDA: Keys for Success. Jenna Stump, MS, CCRP Clinical Research Regulatory Specialist
Maintaining your Investigational Device Exemption (IDE) with the FDA: Keys for Success Jenna Stump, MS, CCRP Clinical Research Regulatory Specialist Agenda How an investigator should prepare and submit
More informationOfficial Journal of the European Union. (Acts whose publication is obligatory)
5.11.2003 L 287/1 I (Acts whose publication is obligatory) REGULATION (EC) No 1946/2003 OF THE EUROPEAN PARLIAMT AND OF THE COUNCIL of 15 July 2003 on transboundary movements of genetically modified organisms
More informationCode of Business Conduct
Reckitt Benckiser Group plc 103-105 Bath Road, Slough, Berkshire SL1 3UH, United Kingdom Tel: +44 (0) 1753 217 800 Fax: +44 (0) 1753 217 899 www.rb.com Code of Business Conduct Reckitt Benckiser is committed
More informationRecommendations for Strengthening the Investigator Site Community
Recommendations for Strengthening the Investigator Site Community October 2017 CTTI MISSION: To develop and drive adoption of practices that will increase the quality and efficiency of clinical trials
More informationBayer Corporate Policy: Global Publications Deriving from Clinical Studies in Humans
Bayer Corporate Policy: Global Publications Deriving from Clinical Studies in Humans Overview The key aspects of this Global Publication Policy are commitment to publish; consistent application of authorship
More informationApplicability of US Regulations to Canadian Research
Applicability of US Regulations to Canadian Research Mary Kate Needler Capital District Health Authority Halifax, Nova Scotia, Canada N2 Stakeholder Meeting August 18, 2014 MK s Conventions: 1. US Regulation
More informationClinical Trials in Taiwan Regulatory Achievement and Current Status
Clinical Trials in Taiwan Regulatory Achievement and Current Status Hui-Po Wang, Ph.D. Director General, Bureau of Pharmaceutical Affairs, Department of Health, Taiwan Sue, Shu-Yi Chen, Pharmacist Division
More informationInternational Transfers of Personal Data at sanofi-aventis R & D
International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF
More informationChicony Electronics Co., Ltd. Ethical Corporate Management Best Practice Principles
Chicony Electronics Co., Ltd. Ethical Corporate Management Best Practice Principles Article I. Article II. Article III. Article IV. Article V. Article VI. These Ethical Corporate Management Best Practice
More informationDHT HOLDINGS, INC. CODE OF BUSINESS CONDUCT AND ETHICS
November 2012 DHT HOLDINGS, INC. CODE OF BUSINESS CONDUCT AND ETHICS Introduction This Code of Business Conduct and Ethics (the Code ) summarizes the values, principles and the business practices which
More informationETHICAL CODE OF CONDUCT
S E C U R I N G T H E F U T U R E ETHICAL CODE OF CONDUCT 1 TABLE OF CONTENT 1. THE ETHICAL CODE OF CONDUCT 4 1.1 Purpose 4 1.2 Commitment 5 1.3 Presentation of the Code of Conduct 5 2. GENERAL PRINCIPLES
More informationCODE OF CONDUCT FOR DOING BUSINESS WITH LINKEDIN
CODE OF CONDUCT FOR DOING BUSINESS WITH LINKEDIN TABLE OF CONTENTS INTRODUCTION 1 Expectations LINKEDIN VALUES 2 MAINTAINING BUSINESS INTEGRITY 3 Anti-Corruption Competition Laws PROMOTING TRANSPARENCY
More informationTOP 10 INVESTIGATOR RESPONSIBILITIES WHEN CONDUCTING HUMAN SUBJECTS RESEARCH
Investigators Responsibility #1: Design and Implement Ethical Research Consistent with the Three Ethical Principles Delineated in The Belmont Report. The Belmont Report: Three Basic Ethical Principles:
More informationSponsorship of Clinical Research Studies
Sponsorship of Clinical Research Studies Category: Summary: Equality Impact Assessment undertaken: Policy The UK Policy Framework for Health and Social Care 2017 (UKPF) and The Medicines for Human Use
More informationChina Airlines Co., Ltd. Corporate Social Responsibility and Sustainable Development Best Practice Principles. Chapter I General Principles
China Airlines Co., Ltd. Corporate Social Responsibility and Sustainable Development Best Practice Principles Approved by the 6 th meeting of the 20 th term board of directors on May 12, 2016 Approved
More informationClinical Trial Transparency UK perspective
Clinical Trial Transparency UK perspective Dr Bina Rawal Medical, Innovation & Research Director Association of the British Pharmaceutical Industry January 2014 1 Outline Transparency timeline Campaign
More informationRELM WIRELESS CORPORATION (the Company ) CODE OF BUSINESS CONDUCT AND ETHICS
RELM WIRELESS CORPORATION (the Company ) CODE OF BUSINESS CONDUCT AND ETHICS Introduction This Code of Business Conduct and Ethics covers a wide range of business practices and procedures. It does not
More informationThe 92Q Celebrity Christmas Sweepstakes 2017
The 92Q Celebrity Christmas Sweepstakes 2017 OFFICIAL SWEEPSTAKES RULES NO PURCHASE NECESSARY TO ENTER OR WIN. A PURCHASE WILL NOT INCREASE A PARTICIPANT S CHANCES OF WINNING. SWEEPSTAKES DESCRIPTION:
More informationGUIDANCE FOR SUPPLIERS OF PURDUE PHARMA L.P.
GUIDANCE FOR SUPPLIERS OF PURDUE PHARMA L.P. PURDUE PHARMA L.P. PURDUE S GUIDING PRINCIPLES 1 Table of Contents PURDUE S GUIDING PRINCIPLES... 1 ETHICAL BUSINESS PRACTICES... 4 Business Integrity... 4
More informationProcedure: Sasol Supplier code Of Ethics
Procedure: Sasol Supplier code Of Ethics >Document number< Revision: 01 SAX-10029304 Purpose This Procedure is intended to govern the Conduct of Sasol and all of its subsidiaries, sub-contractors, consultants,
More informationIRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010
IRB-GCP and Timelines Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October 11-14 th, 2010 1 Factors that affect Timelines Finalized Protocol Finalized
More informationCODE OF ETHICS AND PROFESSIONAL CONDUCT
CODE OF ETHICS AND PROFESSIONAL CONDUCT Preamble Members of The American Institute of Architects are dedicated to the highest standards of professionalism, integrity, and competence. This Code of Ethics
More informationRegulatory and ethical requirements in medical device studies. Finland
Regulatory and ethical in medical device studies Finland SECTIONS A.Type of research SECTIONS A.Type of research We have differentiated 8 types of research: Medical device alone with CE mark use within
More informationBiomedical Research on Human Participants
Ethical Guidelines for Biomedical Research on Human Participants Dr P Paul Kumaran MBBS, BA (Psychology), MPH Scientist E [Deputy Director Medical] National Institute for Research in Tuberculosis (ICMR)
More informationWCG ACADEMY COURSE OVERVIEW
WCG ACADEMY COURSE OVERVIEW Investigator Course Title Documentation of Informed Consent Duration Ethical Principles Underlying Consent Documentation Long Form Short Form Consent Records Special Considerations
More informationData Protection Policy
Data Protection Policy StCH Data Protection Policy - POL 53 vs1 - July 2016 1 Document Control Table Document Title: Data Protection Policy Document Ref: POL 53 Author (name and job title): Karen Anderson,
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 3 19 June 2012 EMA/119871/2012 4 5 Guideline on good pharmacovigilance practices (GVP) Module III Pharmacovigilance inspections Draft finalised by the Agency in collaboration with Member States and
More informationGeneral Personal Data Protection Policy
General Personal Data Protection Policy Contents 1. Scope, Purpose and Users...4 2. Reference Documents...4 3. Definitions...5 4. Basic Principles Regarding Personal Data Processing...6 4.1 Lawfulness,
More informationClinical trial information leaflet and consent
Informed consent 1(7) Clinical trial information leaflet and consent General You must provide sufficient information on the rights of clinical trial subjects, the purpose and nature of the trial, the methodologies
More information1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.
1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended
More informationBest Buy Political Activity &
Page 1 of 7 A. Policy Overview Purpose: This policy seeks to educate employees on political activity as it pertains to employment with Best Buy as a U.S.-domiciled company. Best Buy encourages employees
More informationclarify the roles of the Department and minerals industry in consultation; and
Procedures for Crown Consultation with Aboriginal Communities on Mine Development Projects Mineral Resources Division, Manitoba Science, Technology, Energy and Mines The Government of Manitoba recognizes
More informationThe 2014 Casino du Lac-Leamy Sound of Light Best Show Award and Contest TERMES AND CONDITIONS
Terms and conditions Best Show Award 2014 The 2014 Casino du Lac-Leamy Sound of Light Best Show Award and Contest TERMES AND CONDITIONS Only Casino du Lac-Leamy Sound of Light spectators are eligible to
More informationComputer Programs and Systems, Inc. Code of Business Conduct and Ethics
(as of January 28, 2013) Introduction This sets forth the guiding principles by which we operate Computer Programs and Systems, Inc. (the Company ) and conduct our daily business with our stockholders,
More informationChin Koerner Executive Director US Regulatory and Development Policy
Chin Koerner Executive Director US Regulatory and Development Policy Novartis Pharmaceuticals Corporation 1700 Rockville Pike Suite 510 Rockville, MD 20852 Tel 301.468.5607 Fax 301.468.5614 Email: Chin.Koerner@novartis.com
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Ireland Question 1: What laws or regulations apply to an application for conducting a clinical
More informationIdentity Provider Policy. Identity and Authentication Services (IA Services)
Identity Provider Policy Identity and Authentication Services (IA Services) Table of Contents 1 Background... 1 1.1 ehealth Ontario Identity Federation... 1 1.2 Purpose... 1 1.3 Objectives... 1 1.4 Scope
More informationLiving Our Purpose and Core Values CODE. Code of Business Ethics and Conduct for Vendors
Living Our Purpose and Core Values CODE Code of Business Ethics and Conduct for Vendors December 2016 HCSC Vendor Code of Business Ethics and Conduct Since 1936, Health Care Service Corporation, a Mutual
More informationGovernance Policies for PCORnet, the National Patient-Centered Clinical Research Network
Governance Policies for PCORnet, the National Patient-Centered Clinical Research Network 1.0 Leadership and Decision-Making When reading this document it is important to note that there are several categories
More informationMEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155
MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155 EXECUTIVE SUMMARY Medical device regulations around the world generally require manufacturers of most types of medical devices to supply data as part
More informationSUPPLIER CODE OF CONDUCT
SUPPLIER CODE OF CONDUCT Philip Morris USA U.S. Smokeless Tobacco Company John Middleton Ste. Michelle Wine Estates Philip Morris Capital Corporation Nu Mark Our companies are committed to responsibly
More informationGlobal Clinical Trials in Korea
Global Clinical Trials in Korea In-Sook Park Department of Drug Evaluation Korea Food & Drug Administration Contents Regulatory changes relevant to Clinical Trials in Korea Current Status of Clinical Trials
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationSunshine on Europe: impact of recent EFPIA and EU guidelines on publication planners. Susan Scott, PhD, CMPP Director, Scott Pharma Solutions Ltd
Sunshine on Europe: impact of recent EFPIA and EU guidelines on publication planners Susan Scott, PhD, CMPP Director, Scott Pharma Solutions Ltd Disclaimer As an independent consultant, the views expressed
More informationBERMAZ AUTO BERHAD (formerly known as Berjaya Auto Berhad) (Company No M) BOARD CHARTER
(formerly known as Berjaya Auto Berhad) (Company No. 900557-M) BOARD CHARTER 1. INTRODUCTION The Board of Directors ( the Board ) is responsible for the performance and affairs of the Company and its subsidiaries
More informationPUBLIC AUTHORITY BOARD MEMBER DUTIES Anita Laremont, SVP - Legal & General Counsel Empire State Development Corporation December 2005
PUBLIC AUTHORITY BOARD MEMBER DUTIES Anita Laremont, SVP - Legal & General Counsel Empire State Development Corporation December 2005 I. The duties and legal responsibilities of board of director members
More informationDraft proposal for an addendum, on transparency, to the Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014
20 January 2015 EMA/641479/2014 Compliance and Inspections Draft proposal for an addendum, on transparency, to the Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014
More informationINTERNATIONAL STANDARD ON AUDITING 260 COMMUNICATION WITH THOSE CHARGED WITH GOVERNANCE CONTENTS
Introduction INTERNATIONAL STANDARD ON AUDITING 260 COMMUNICATION WITH THOSE CHARGED WITH GOVERNANCE (Effective for audits of financial statements for periods beginning on or after December 15, 2009) +
More informationBOARD GUIDELINES ON SIGNIFICANT CORPORATE GOVERNANCE ISSUES
BOARD GUIDELINES ON SIGNIFICANT CORPORATE GOVERNANCE ISSUES Management and the Board of Directors ( Board ) of Nabors Industries Ltd. (the Company ) are committed to conducting business consistent with
More informationCODE OF CONDUCT COMPLIANCE GUIDELINE
1. PREAMBLE AND ORIENTATION Our Code of Conduct shall present orientation and shall encourage the right conduct in those departments in which our employees are being faced with legal and ethical questions
More informationHRPP Policy No. 714 Effective Date 09/01/10 Revisions Date. Genome Wide Association Studies
Genome Wide Association Studies HRPP Policy No. 714 Effective Date 09/01/10 Revisions Date 1.0 Purpose This policy describes how investigators at the University of South Florida (USF) and USF Affiliates
More informationATTACHMENT C CORPORATE COMPLIANCE PROGRAM
ATTACHMENT C CORPORATE COMPLIANCE PROGRAM In order to address deficiencies in its internal controls, policies, and procedures regarding compliance with the Foreign Corrupt Practices Act ( FCPA ), 15 U.S.C.
More informationWhat is an IRB (Institutional Review Board)?
What is an IRB (Institutional Review Board)? The Belmont Report The Belmont Report on the Ethical Principles and Guidelines for the Protection of Human Subjects of Research was prepared by the National
More informationWMA Declaration of Helsinki - Ethical
WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects Download the PDF file Adopted by the 18 th WMA General Assembly, Helsinki, Finland, June 1964 and amended
More informationTELUS Supplier Code of Conduct
TELUS Supplier Code of Conduct April 2014 NEXT TELUS Supplier Code of Conduct 2 Contents Introduction... 3 Ethics... 4-5 Business Integrity... 4 No Improper Advantage... 4 Disclosure of Information...
More informationCODE OF ETHICS FOR CHIEF EXECUTIVE OFFICER AND SENIOR FINANCIAL OFFICERS UGI CORPORATION
CODE OF ETHICS FOR CHIEF EXECUTIVE OFFICER AND SENIOR FINANCIAL OFFICERS OF UGI CORPORATION Introduction The reputation for integrity of UGI Corporation (the Company ) is a valuable asset that is vital
More informationCODE OF ETHICS AND BUSINESS CONDUCT
CODE OF ETHICS AND BUSINESS CONDUCT 1.0 SCOPE This Code of Ethics and Business Conduct (the Code of Conduct ) is implemented by the Board of Directors (the Board ) of Dominion Diamond Corporation and applies
More information\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management
Five Content Areas Percent of Scored Test Items (Range) in Each Area This table shows the percent of scored test questions that are included in each major content area. Five Content Areas Ethical Principles
More informationReview PROCESS, decision making PROCESS and communication BY
Review PROCESS, decision making PROCESS and communication BY ethics committee Dr. Reneega Gangadhar, Professor & Head Department of Pharmacology Govt. Medical college Trivandrum Outline Review process
More informationBest Buy Political Activity & Government Relations Policy
Best Buy Political Activity & Government Relations Policy Employee Policy B e s t B u y C o., I n c. G o v e r n m e n t R e l a t i o n s D e p a r t m e n t This policy seeks to educate employees on
More informationRadiation - Florida Department of Health Institutional Review Board
500-26 Radiation 500-26 Radiation - Florida Department of Health Institutional Review Board Protocol title: Researcher: Application contact: For questions, concerns, to provide input, or request a consultation,
More informationStandard on Assurance Engagements ASAE 3500 Performance Engagements
ASAE 3500 (July 2008) (Amended October 2008) Standard on Assurance Engagements ASAE 3500 Issued by the Auditing and Assurance Standards Board Obtaining a Copy of this Standard on Assurance Engagements
More informationREGIONAL HEALTH AUTHORITIES ACT
Province of Alberta REGIONAL HEALTH AUTHORITIES ACT Revised Statutes of Alberta 2000 Chapter R-10 Current as of June 17, 2014 Office Consolidation Published by Alberta Queen s Printer Alberta Queen s Printer
More informationCode of Conduct for the Board of Directors and the Senior Management Personnel
GLOBE INTERNATIONAL CARRIERS LIMITED Code of Conduct for the Board of Directors and the Senior Management Personnel [as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015] 1.
More informationPrivacy Policy PURPOSE SCOPE POLICY. Data Collection
Privacy Policy PURPOSE 1. To ensure Training & Assessment Mentor maintains the privacy of personal information provided to Training & Assessment Mentor from Staff and Students. SCOPE 2. This document describes
More informationWorld Medical Association Declaration of Helsinki
World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18th WMA General Assembly Helsinki, Finland, June 1964 and amended by the
More informationResponsibility Standards for Suppliers
Responsibility Standards for Suppliers 2017 GLOBAL PROCUREMENT Our Credo We believe our first responsibility is to the doctors, nurses and patients, to mothers and fathers and all others who use our products
More informationMeasures on Open Environmental Information (for Trial Implementation)
Measures on Open Environmental Information (for Trial Implementation) (Adopted by the State Environmental Protection Administration of China on February 8, 2007; Effective May 1, 2008) Chapter I. General
More informationStandard Operating Procedures Guidelines for Good Clinical Practice
SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA
More informationQuality Assurance in Clinical Trials
Quality Assurance in Clinical Trials Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 5th, 2011 1 Introduction: quality in clinical research in human subjects Regulatory requirements:
More informationBusiness Conduct Requirements for Representatives and Channel Partners
Business Conduct Requirements for Representatives and Channel Partners www.qorvo.com Qorvo, Inc. and its affiliates ( Qorvo ) are committed to the highest standards of business conduct and ethics and expect
More informationTAP AUTOMOTIVE HOLDINGS, LLC TAP WORLDWIDE, LLC / TAP MANUFACTURING, LLC Code of Conduct and Business Ethics
Revised and Reissued August 2015 TAP AUTOMOTIVE HOLDINGS, LLC TAP WORLDWIDE, LLC / TAP MANUFACTURING, LLC Code of Conduct and Business Ethics THIS POLICY DOES NOT CREATE AN EXPRESS OR IMPLIED EMPLOYMENT
More informationCODE OF CONDUCT Version 3 August 2016
CODE OF CONDUCT Version 3 August 2016 Table of Contents 1. INTRODUCTION... 3 2. COMPLIANCE WITH LOCAL LAWS AND REGULATIONS... 3 3. FAIR COMPETITION... 4 4. ANTI BRIBERY AND ANTI CORRUPTION... 4 5. WORKING
More information